Metformin: the next angiogenesis panacea?
/PMC/2021
Why It Matters
Describes metformin as promoting VEGF-mediated angiogenesis, despite being one of the most widely prescribed medications globally. Demonstrates that pro-angiogenic ≠ pro-cancer.
Key Findings
- Metformin promotes VEGF-mediated angiogenesis at therapeutic doses
- Despite being pro-angiogenic, metformin is associated with reduced cancer risk
Read the Paper↗PMC7970164